Impact of Calcineurin Inhibitors on Hepatitis C Recurrence After Liver Transplantation

Background and Aims The aim of this retrospective study is to assess the impact of calcineurin inhibitors on hepatitis C virus recurrence following liver transplantation. Methods A total of 396 patients underwent liver transplantation for hepatitis C virus-induced liver disease between 1991 and 2005...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2012-02, Vol.57 (2), p.568-572
Main Authors: Kim, Robin D., Mizuno, Shugo, Sorensen, John B., Schwartz, Jason J., Fujita, Shiro
Format: Article
Language:English
Subjects:
Biochemistry
Calcineurin Inhibitors
Cyclosporine
Cyclosporine - therapeutic use
Diseases
Female
Gastroenterology
Graft Survival
Hepatitis C - immunology
Hepatitis C - prevention & control
Hepatitis C virus
Hepatology
Humans
Immunosuppressive Agents - therapeutic use
Immunotherapy
Liver
Liver Transplantation - immunology
Male
Medicine
Medicine & Public Health
Middle Aged
Multivariate Analysis
Oncology
Original Article
Relapse
Retrospective Studies
Risk Factors
RNA
Secondary Prevention
Tacrolimus
Tacrolimus - therapeutic use
Transplant Surgery
Transplantation
Transplantation, Homologous
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aims The aim of this retrospective study is to assess the impact of calcineurin inhibitors on hepatitis C virus recurrence following liver transplantation. Methods A total of 396 patients underwent liver transplantation for hepatitis C virus-induced liver disease between 1991 and 2005 at a single center. We examined the pre- and post-operative characteristics of patients who received either cyclosporine ( n  = 126) or tacrolimus ( n  = 270) as maintenance immunosuppression. In addition, we compared the postoperative course, including patient, graft and hepatitis C virus recurrence-free survival between the two groups. Results There were no significant differences between the two groups in either post-operative hepatitis C virus—ribonucleic acid or histological fibrosis score (performed within 6 months after transplant per protocol). The graft and patient survivals did not differ between the two groups (logrank p  = 0.34 and 0.15, respectively). Histologic hepatitis C virus recurrence-free survival, however, was significantly higher in the cyclosporine group than in the tacrolimus group (55.4 vs. 30.8% at 1 year, 18.6 vs. 10.3% at 3 years, 16.7 vs. 8.1% at 5 years, p  
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-011-1871-z